SIGA Faces Key Test on Call Amid New Contracts and Tpoxx Questions

NEW YORK, NY – March 03, 2026 – SIGA Technologies is poised for a pivotal moment as the company announced it will host a business update call on March 10 to discuss its full-year 2025 financial results. While the numbers will provide a concrete measure of the past year's performance, investors and public health stakeholders are looking further ahead, seeking clarity on the company's trajectory in the complex and often unpredictable biodefense market.

The call, featuring CEO Diem Nguyen and CFO Daniel Luckshire, comes at a critical juncture. SIGA's fortunes are intrinsically linked to its flagship antiviral, Tpoxx (tecovirimat), and the government contracts that support its production and stockpiling. With key contracts fulfilled and new ones on the horizon, the upcoming update is expected to provide crucial insights into SIGA's strategy for achieving durable growth beyond its existing agreements.

A Look Back at a Financially Mixed 2025

Heading into the announcement, SIGA's financial story from 2025 has been one of significant but uneven performance. The first nine months of the year were strong, with total revenues hitting $90.8 million, a substantial increase from $57.3 million in the same period of 2024. This surge was primarily fueled by large deliveries of Tpoxx to the U.S. Strategic National Stockpile (SNS) under its contract with the Biomedical Advanced Research and Development Authority (BARDA).

Specifically, the second quarter of 2025 saw the company generate $79 million in product revenues from deliveries of both oral and intravenous Tpoxx to the SNS. These deliveries were part of the roughly $70 million in outstanding orders the company carried into the year. However, the lumpy nature of government procurement was highlighted in the third quarter, when SIGA reported a net loss of approximately $6 million on revenues of just $2.62 million, a stark contrast to the prior quarter's success. This fluctuation underscores the company's dependence on the timing of large government orders.

Investors will be eager to see the full-year figures to understand how fourth-quarter activities balanced the books. A key focus will be on the company's robust balance sheet; as of September 30, 2025, SIGA reported a cash balance of approximately $172 million with no debt, providing significant operational flexibility.

Tpoxx: A Cornerstone with Evolving Challenges

SIGA's market position is dominated by Tpoxx, an essential countermeasure for orthopoxviruses like smallpox. The drug is approved by the U.S. FDA for smallpox and holds broader approvals in Europe, the UK, and most recently Japan, for treating a range of orthopoxvirus infections, including mpox (formerly monkeypox).

This reliance on a single core product makes news surrounding its efficacy and market access paramount. A significant development has been the initial results from two randomized clinical studies, PALM007 and STOMP, which assessed Tpoxx's use in treating mpox. While the drug was found to be safe, the studies showed it did not reduce the time to lesion resolution compared to a placebo. This finding has created a complex narrative for the company, as it simultaneously pursues wider international adoption for mpox while navigating questions about the drug's clinical benefit for that specific indication. These results have reportedly led to questions from the European Medicines Agency (EMA), creating potential headwinds for its standing in the EU.

Despite these challenges, SIGA has continued to expand its global footprint. In January 2025, it secured regulatory approval in Japan, a significant milestone that marks the first antiviral approved by the nation's regulators for orthopoxviruses. The company has also fulfilled procurement orders from 30 countries over the past three years, demonstrating a growing international market for biodefense preparedness.

Anticipating the Path Forward

Beyond the 2025 results, the March 10 call will be most scrutinized for its forward-looking statements. The investment community is keenly focused on two potential catalysts that could fundamentally reshape SIGA's valuation and long-term revenue stream.

The first and most immediate is the status of a new, long-term procurement contract with the U.S. government. The current 19C BARDA contract, valued at up to $629 million, has been the primary engine of SIGA's revenue. With analysts anticipating a request for proposal for a follow-on contract in the coming months, any commentary from management on the timing, scope, and potential value of a new agreement will be a major focus. In March 2025, the government did exercise a $26 million option for IV Tpoxx to be delivered in 2026, signaling continued commitment, but a larger, multi-year contract is seen as essential for long-term stability.

The second major catalyst is the planned submission for a Post-Exposure Prophylaxis (PEP) indication for Tpoxx in the United States. SIGA has targeted the first half of 2026 for this FDA submission. A PEP indication would allow Tpoxx to be administered to individuals after exposure to smallpox but before symptoms appear, significantly broadening its use case. This could not only increase the per-unit value of the drug but also expand the potential size of government stockpiles, making it a key value driver in analysts' models.

As SIGA prepares to address its stakeholders, it navigates a landscape of immense opportunity and significant challenges. The company must articulate a clear strategy for securing its next wave of foundational contracts while managing the scientific and regulatory discourse around Tpoxx's role in the evolving threat of infectious diseases. The upcoming call will be a critical platform to assure investors that the company is prepared to build upon its health security leadership for years to come.